H Conjeevaram's research while affiliated with The National Institute of Diabetes and Digestive and Kidney Diseases and other places

Citations

... However, clinical experience with the use of methotrexate in the treatment of PBC is becoming substantial. [13][14][15][16][17][18][19][20] A large, rigorously conducted, multicenter, randomized, placebo-controlled trial of a combination of methotrexate and UDCA in patients with PBC has been underway in the United States for several years. 21 The definitive results of this important trial are awaited. ...
... These data are consistent with those observed in postmenopausal osteoporosis, 37 but are in disagreement with those reported in patients with PBC. Actually, the VDR polymorphism has been proposed as a predictor of bone loss, 42 and a significant predictor of decreased BMD in patients with PBC. 43 In this latter study, patients homozygous for the b allele had lower spine BMD than those who were heterozygous or homozygous for the B allele, which is the allele commonly associated with low bone mass in most studies. ...
... Ribavirin had been explored for the treatment of HCV contamination in the mid 1990s. Notwithstanding perceptions of upgrades in serum aminotransferase levels [6] and hepatic histology [7], ribavirin had no huge impact on HCV RNA levels when utilized as a solitary operator. As respects virology freedom, drawing out the course of treatment didn't give any profit (Hoofnagle et al., 1996). ...